Targeting MYC-driven lymphoma: lessons learned and future directions

Abstract

MYC plays a central role in tumorigenesis by orchestrating cell proliferation, growth and survival, among other transformation mechanisms. In particular, MYC has often been associated with lymphomagenesis. In fact, MYC overexpressing lymphomas such as high-grade B-cell lymphoma (HGBL) and double expressor diffuse large B-cell lymphomas (DLBCL), are considered addicted to MYC. In such a context, MYC targeting therapies are of special interest, as MYC withdrawal is expected to result in tumor regression. However, whether high MYC levels are always predictive of increased sensitivity to these approaches is not clear yet. Even though no MYC inhibitor has received regulatory approval to date, substantial efforts have been made to investigate avenues to render MYC a druggable target. Here, we summarize the different classes of molecules currently under development, which mostly target MYC indirectly in aggressive B-cell lymphomas, paying special attention to subtypes with MYC/BCL2 or BCL6 translocations or overexpression.

Keywords

High-grade B-cell lymphoma / double expressor lymphoma / MYC / MYC therapies

References

[1] Jaffe ES.Diagnosis and classification of lymphoma: Impact of technical advances.Semin Hematol2019;56:30-6 PMCID:PMC7394061

[2] Mugnaini EN.Lymphoma.Prim Care2016;43:661-75

[3] GLOBOCAN. Cancer Today. Estimated number of new cases in 2020, worldwide, both sexes, all ages. Available from: https://gco.iarc.fr/today/online-analysis-pie?v=2020&mode=population&mode_population=regions&population=900&populations=900&key=total&sex=0&cancer=34&type=0&statistic=5&prevalence=0&population_group=0&ages_group%5B%5D=0&ages_group%5B%5D=17&nb_items=7&group_cancer=1&include_nmsc=1&include_nmsc_other=1&half_pie=0&donut=0 [Last accessed on 11 Apr 2023]

[4] Alaggio R,Anagnostopoulos I.The 5th edition of the world health organization classification of haematolymphoid tumours: lymphoid neoplasms.Leukemia2022;36:1720-48 PMCID:PMC9214472

[5] Campo E,Cook JR.The international consensus classification of mature lymphoid neoplasms: a report from the clinical advisory committee.Blood2022;140:1229-53

[6] Thandra KC,Saginala K,Barsouk A.Epidemiology of non-Hodgkin’s lymphoma.Med Sci2021;9 PMCID:PMC7930980

[7] Falini B.Comparison of the international consensus and 5th WHO edition classifications of adult myelodysplastic syndromes and acute myeloid leukemia.Am J Hematol2023;98:481-92

[8] Zhuang Y,Wu M.Altered pathways and targeted therapy in double hit lymphoma.J Hematol Oncol2022;15:26 PMCID:PMC8932183

[9] Mehta A,Gupta G,Sharma A.Double hit and double expresser diffuse large B cell lymphoma subtypes: discrete subtypes and major predictors of overall survival.Indian J Hematol Blood Transfus2020;36:627-34 PMCID:PMC7572989

[10] Khelfa Y,Jamil MO.Double-hit large B cell lymphoma.Curr Oncol Rep2017;19:74

[11] Chiappella A,Guidetti A,Armand P.Are we ready to treat diffuse large B-cell and high-grade lymphoma according to major genetic subtypes?.HemaSphere2019;3:e284 PMCID:PMC6919463

[12] Azizian NG,Pham LV.Rational targeted therapeutics for double-hit lymphoma.Int J Hematol Oncol2019;8:IJH19 PMCID:PMC6912852

[13] Di M,Olszewski AJ.Challenges and opportunities in the management of diffuse large B-cell lymphoma in older patients. 2021;26:120-32. PMCID:PMC7873335

[14] Dunleavy K.Double-hit lymphoma: optimizing therapy.Hematology2021;2021:157-63 PMCID:PMC8791152

[15] Frazer JK,Galardy PJ.Excellent outcomes in children and adolescents with CNS⁺ Burkitt lymphoma or other mature B-NHL using only intrathecal and systemic chemoimmunotherapy: results from FAB/LMB96 and COG ANHL01P1.Br J Haematol2019;185:374-7 PMCID:PMC6588172

[16] Saleh K,Camara-Clayette V,Ribrag V.Burkitt and burkitt-like lymphomas: a systematic review.Curr Oncol Rep2020;22:33

[17] Hann SR.MYC cofactors: molecular switches controlling diverse biological outcomes.Cold Spring Harb Perspect Med2014;4:a014399 PMCID:PMC4143105

[18] Dang CV.MYC on the path to cancer.Cell2012;149:22-35 PMCID:PMC3345192

[19] Schaub FX,Berger AC.Pan-cancer alterations of the MYC oncogene and its proximal network across the cancer genome atlas.Cell Syst2018;6:282-300 e2

[20] Gabay M,Felsher DW.MYC activation is a hallmark of cancer initiation and maintenance.Cold Spring Harb Perspect Med2014;4 PMCID:PMC4031954

[21] Dhillon P.In conversation with Gerard evan.FEBS J2019;286:4824-31

[22] Daniel PT,Belka C.Guardians of cell death: the Bcl-2 family proteins.Essays Biochem2003;39:73-88

[23] Klanova M.BCL-2 proteins in pathogenesis and therapy of B-cell non-hodgkin lymphomas.Cancers2020;12 PMCID:PMC7226356

[24] Adams CM,Porcu P.Targeting the Bcl-2 family in B cell lymphoma.Front Oncol2018;8:636 PMCID:PMC6331425

[25] Kapoor I,Hill BT,Almasan A.Targeting BCL-2 in B-cell malignancies and overcoming therapeutic resistance.Cell Death Dis2020;11:941 PMCID:PMC7608616

[26] Strasser A,Bath ML.Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2.Nature1990;348:331-3

[27] Fairlie WD.Co-operativity between MYC and BCL-2 pro-survival proteins in cancer.Int J Mol Sci2021;22 PMCID:PMC8000576

[28] Basso K.BCL6: master regulator of the germinal center reaction and key oncogene in B cell lymphomagenesis.Adv Immunol2010;105:193-210

[29] Basso K.Roles of BCL6 in normal and transformed germinal center B cells.Immunol Rev2012;247:172-83

[30] Yang H.Epigenetic programing of B-cell lymphoma by BCL6 and its genetic deregulation.Front. Cell Dev Biol2019;7:272 PMCID:PMC6853842

[31] Swerdlow SH.Diagnosis of “double hit” diffuse large B-cell lymphoma and B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and Burkitt lymphoma: when and how, FISH versus IHC.Hematol Am Soc Hematol Educ Program2014;2014:90-9

[32] Riedell PA.Double hit and double expressors in lymphoma: definition and treatment.Cancer2018;124:4622-32

[33] Cheah CY,Westin JR.A clinician’s guide to double hit lymphomas.Br J Haematol2015;168:784-95

[34] Quesada AE,Desai PA.Increased MYC copy number is an independent prognostic factor in patients with diffuse large B-cell lymphoma.Mod Pathol2017;30:1688-97

[35] Scott DW,Staiger AM.High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology.Blood2018;131:2060-4

[36] Aurer I,Dreyling M.PF322 approach to double hit lymphoma (DHL) diagnosis and treatment in europe - a cross-section study of EHA lymphoma working party (EHA LYG).HemaSphere2019;3(S1):113-4

[37] Nowakowski GS.ABC, GCB, and double-hit diffuse large B-Cell lymphoma: does subtype make a difference in therapy selection? 2015:e449-e57.

[38] Ennishi D,Boyle M.Double-hit gene expression signature defines a distinct subgroup of germinal center B-cell-like diffuse large B-cell lymphoma.J Clin Oncol2019;37:190-201 PMCID:PMC6804880

[39] Sha C,Cucco F.Molecular high-grade B-cell lymphoma: defining a poor-risk group that requires different approaches to therapy.J Clin Oncol2019;37:202-12 PMCID:PMC6338391

[40] Cucco F,Sha C.Distinct genetic changes reveal evolutionary history and heterogeneous molecular grade of DLBCL with MYC/BCL2 double-hit.Leukemia2020;34:1329-41 PMCID:PMC7192846

[41] Felsher DW.Reversible tumorigenesis by MYC in hematopoietic lineages.Mol Cell1999;4:199-207

[42] Jain M,Chu K.Sustained loss of a neoplastic phenotype by brief inactivation of MYC.Science2002;297:102-4

[43] Pelengaris S,Evan GI.Suppression of Myc-induced apoptosis in beta cells exposes multiple oncogenic properties of Myc and triggers carcinogenic progression.Cell2002;109:321-34

[44] Marinkovic D,Mahr B,Wirth T.Reversible lymphomagenesis in conditionally c-MYC expressing mice.Int J Cancer2004;110:336-42

[45] Soucek L,Martins CP.Modelling Myc inhibition as a cancer therapy.Nature2008;455:679-83 PMCID:PMC4485609

[46] Soucek L,Sodir NM.Inhibition of Myc family proteins eradicates KRas-driven lung cancer in mice.Genes Dev2013;27:504-13 PMCID:PMC3605464

[47] Mita MM.Bromodomain inhibitors a decade later: a promise unfulfilled?.Br J Cancer2020;123:1713-4 PMCID:PMC7722711

[48] Chen H,Zheng L,Shi L.BET inhibitors: an updated patent review (2018-2021).Expert Opin Ther Pat2022;32:953-68

[49] Johnson-Farley N,Bhagavathi S.ABT-199, a BH3 mimetic that specifically targets Bcl-2, enhances the antitumor activity of chemotherapy, bortezomib and JQ1 in “double hit” lymphoma cells.Leuk Lymphoma2015;56:2146-52

[50] Cinar M,Rokhsar S.Concurrent inhibition of MYC and BCL2 is a potentially effective treatment strategy for double hit and triple hit B-cell lymphomas.Leuk Res2015;39:730-8

[51] Esteve-Arenys A,Chamorro-Jorganes A.The BET bromodomain inhibitor CPI203 overcomes resistance to ABT-199 (venetoclax) by downregulation of BFL-1/A1 in in vitro and in vivo models of MYC⁺/BCL2⁺ double hit lymphoma.Oncogene2018;37:1830-44

[52] Shorstova T,Witcher M.Achieving clinical success with BET inhibitors as anti-cancer agents.Br J Cancer2021;124:1478-90 PMCID:PMC8076232

[53] Li W,Han W.Targeting MYC activity in double-hit lymphoma with MYC and BCL2 and/or BCL6 rearrangements with epigenetic bromodomain inhibitors.J Hematol Oncol2019;12:73 PMCID:PMC6617630

[54] Dickinson M,Herrera AF.Phase 1b study of the BET protein inhibitor RO6870810 with venetoclax and rituximab in patients with diffuse large B-cell lymphoma.Blood Adv2021;5:4762-70 PMCID:PMC8759125

[55] Winkler R,Piskor EM.Targeting the MYC interaction network in B-cell lymphoma via histone deacetylase 6 inhibition.Oncogene2022;41:4560-72

[56] Ho TCS,Ganesan A.Thirty years of HDAC inhibitors: 2020 insight and hindsight.J Med Chem2020;63:12460-84

[57] Guan XW,Ban WW.Novel HDAC inhibitor Chidamide synergizes with Rituximab to inhibit diffuse large B-cell lymphoma tumour growth by upregulating CD20.Cell Death Dis2020;11:20 PMCID:PMC6944697

[58] Kang J,Ding S.Modified conditioning regimen with chidamide and high-dose rituximab for triple-hit lymphoma.J Cell Mol Med2021;25:10770-3 PMCID:PMC8581337

[59] Luo C,Young KH.HDAC inhibitor chidamide synergizes with venetoclax to inhibit the growth of diffuse large B-cell lymphoma via down-regulation of MYC, BCL2, and TP53 expression.J Zhejiang Univ Sci B2022;23:666-81 PMCID:PMC9381329

[60] Farrell AS.MYC degradation.Cold Spring Harb Perspect Med2014;4 PMCID:PMC3935390

[61] Kim SJ,Yoo HY,Kang KW.Anti-cancer effects of CKD-581, a potent histone deacetylase inhibitor against diffuse large B-cell lymphoma.Int J Mol Sci2020;21 PMCID:PMC7352247

[62] Li H,Ji M.CUDC-101 enhances the chemosensitivity of gemcitabine-treated lymphoma cells.Leuk Res2021;106:106575

[63] Zhang K,Lai F.Bioevaluation of a dual PI3K/HDAC inhibitor for the treatment of diffuse large B-cell lymphoma.Bioorg Med Chem Lett2022;71:128825

[64] Zhang MC,Wang L.Clinical efficacy and molecular biomarkers in a phase II study of tucidinostat plus R-CHOP in elderly patients with newly diagnosed diffuse large B-cell lymphoma.Clin Epigenetics2020;12:160

[65] Landsburg DJ,Ramchandren R.Fimepinostat (CUDC-907) in patients with relapsed/refractory diffuse large B cell and high-grade B-cell lymphoma: report of a phase 2 trial and exploratory biomarker analyses.Br J Haematol2021;195:201-9

[66] Sonawane YA,Napoleon JV,Contreras JI.Cyclin dependent kinase 9 inhibitors for cancer therapy.J Med Chem2016;59:8667-84 PMCID:PMC5636177

[67] Diamond JR,Lim E.First-in-human dose-escalation study of cyclin-dependent kinase 9 inhibitor VIP152 in patients with advanced malignancies shows early signs of clinical efficacy.Clin Cancer Res2022;28:1285-93

[68] Moreno V,Morillo D.Safety and efficacy of VIP152, a CDK9 inhibitor, in patients with double-hit lymphoma (DHL).J Clin Oncol2021;39:7538

[69] Frigault MM,Garban H.VIP152, a selective CDK9 inhibitor, induces complete regression in a high-grade B-cell lymphoma (HGBL) model and depletion of short-lived oncogenic driver transcripts, MYC and MCL1, with a once weekly schedule.Blood2021;138:1192

[70] Ball B,Stein AS,Thai DL.Safety and efficacy of casein kinase 1α and cyclin dependent kinase 7/9 inhibition in patients with relapsed or refractory AML: a first-in-human study of BTX-A51.J Clin Oncol2022;40:7030

[71] Ball BJ,Borthakur G.Trial in progress: a phase I trial of BTX-A51 in patients with relapsed or refractory AML or high-risk MDS.Blood2020;136:18-9

[72] Richters A,Freeman DB.Modulating androgen receptor-driven transcription in prostate cancer with selective CDK9 inhibitors.Cell Chem Biol2021;28:134-47 e14

[73] Day MA,Hood T.CDK9 inhibition via KB-0742 is a potential strategy to treat transcriptionally addicted cancers.Cancer Res2022;82:2564

[74] Mishra R,Alanazi S,Garrett JT.PI3K inhibitors in cancer: clinical implications and adverse effects.Int J Mol Sci2021;22 PMCID:PMC8037248

[75] Chen L,Wienand K.CXCR4 upregulation is an indicator of sensitivity to B-cell receptor/PI3K blockade and a potential resistance mechanism in B-cell receptor-dependent diffuse large B-cell lymphomas.Haematologica2020;105:1361-8 PMCID:PMC7193488

[76] Grande BM,Jiang A.Genome-wide discovery of somatic coding and noncoding mutations in pediatric endemic and sporadic Burkitt lymphoma.Blood2019;133:1313-24 PMCID:PMC6428665

[77] Profitos-Peleja N,Marin-Niebla A,Ribeiro ML.Regulation of B-cell receptor signaling and its therapeutic relevance in aggressive B-cell lymphomas.Cancers2022;14 PMCID:PMC8870007

[78] Stengel S,Sbirkov Y.Suppression of MYC by PI3K/AKT/mTOR pathway inhibition in combination with all-trans retinoic acid treatment for therapeutic gain in acute myeloid leukaemia.Br J Haematol2022;198:338-48

[79] Zhu J,Yuan J.Activation of PI3K/Akt and MAPK pathways regulates Myc-mediated transcription by phosphorylating and promoting the degradation of Mad1.Proc Natl Acad Sci USA2008;105:6584-9 PMCID:PMC2373325

[80] Fan L,Zhao L.SHC014748M, a novel selective inhi-bitor of PI3Kδ, demonstrates promising preclinical antitumor activity in B cell lymphomas and chronic lymphocytic leukemia.Neoplasia2020;22:714-24 PMCID:PMC7586065

[81] Zuo W-Q,Wang W-L.Identification of a potent and selective phosphatidylinositol 3-kinase δ inhibitor for the treatment of non-Hodgkin’s lymphoma.Bioorg Chem2020;105:104344

[82] Chen ZQ,Wang Y.Repressing MYC by targeting BET synergizes with selective inhibition of PI3Kalpha against B cell lymphoma.Cancer Lett2022;524:206-18

[83] Zhang X,Wang Y.SAF-248, a novel PI3Kdelta-selective inhibitor, potently suppresses the growth of diffuse large B-cell lymphoma.Acta Pharmacol Sin2022;43:209-19

[84] Nastoupil LJ,Davis RE.Preclinical and phase I studies of KA2237, a selective and potent inhibitor of PI3K β/δ in relapsed refractory B cell lymphoma.Leuk Lymphoma2021;62:3452-62

[85] Lee BR,Son Mk.Abstract 655: BR101801: a first-in-class triple-inhibitor of PI3K gamma/delta and DNA-PK targeting non-Hodgkin’s lymphoma.Cancer Res2020;80:655

[86] Kim TM,Mattour AH.A phase 1 dose escalation study of dual PI3K and DNA PK inhibitor, BR101801 in adult patients with advanced hematologic malignancies.Blood2021;138:3562

[87] Shin N,Koblish H.Parsaclisib Is a next-generation phosphoinositide 3-kinase δ inhibitor with reduced hepatotoxicity and potent antitumor and immunomodulatory activities in models of B-cell malignancy.J Pharmacol Exp Ther2020;374:211-22

[88] Wang Y,King RL.Parsaclisib in combination with R-CHOP for patients with newly diagnosed diffuse large B-cell lymphoma: preliminary results of a phase 1/1b study.Blood2021;138:1415

[89] Moyo TK,Moore DJ.Myc enhances B-cell receptor signaling in precancerous B cells and confers resistance to Btk inhibition.Oncogene2017;36:4653-61 PMCID:PMC5552428

[90] Ribeiro ML,Vinyoles M.Antitumor activity of the novel BTK inhibitor TG-1701 is associated with disruption of ikaros signaling in patients with B-cell non-hodgkin lymphoma.Clin Cancer Res2021;27:6591-601

[91] Burke GAA,Bhojwani D.Ibrutinib plus CIT for R/R mature B-NHL in children (SPARKLE trial): initial safety, pharmacokinetics, and efficacy.Leukemia2020;34:2271-5 PMCID:PMC7387295

[92] Burke GAA,Kabickova E.Ibrutinib plus RICE/RVICI for R/R mature B-NHL in children/young adults: SPARKLE trial.Blood Adv2022; PMCID:PMC9984435

[93] Yang H,Song Y.Zanubrutinib monotherapy for relapsed or refractory non-germinal center diffuse large B-cell lymphoma.Blood Adv2022;6:1629-36 PMCID:PMC8941452

[94] Barr PM,Roschewski MJ.Phase 1/2 study of acalabrutinib and the PI3K delta inhibitor ACP-319 in relapsed/refractory B-cell non-hodgkin lymphoma.Leuk Lymphoma2022;63:1728-32

[95] Beaulieu ME,Soucek L.Structural and biophysical insights into the function of the intrinsically disordered Myc oncoprotein.Cells2020;9 PMCID:PMC7226237

[96] Gomez-Curet I,Bennett R,Dunn SP.c-Myc inhibition negatively impacts lymphoma growth.J Pediatr Surg2006;41:207-11; discussion

[97] Clausen DM,Parise RA.In vitro cytotoxicity and in vivo efficacy, pharmacokinetics, and metabolism of 10074-G5, a novel small-molecule inhibitor of c-Myc/max dimerization.J Pharmacol Exp Ther2010;335:715-27 PMCID:PMC2993546

[98] Choi SH,Lee SJ.Targeted disruption of Myc-max oncoprotein complex by a small molecule.ACS Chem Biol2017;12:2715-9

[99] Pighi C,Compagno M.Frequent mutations of FBXO11 highlight BCL6 as a therapeutic target in Burkitt lymphoma.Blood Adv2021;5:5239-57 PMCID:PMC9153037

[100] Li X-Y,Liu P.Inhibition of USP1 reverses the chemotherapy resistance through destabilization of MAX in the relapsed/refractory B-cell lymphoma.Leukemia2023;37:164-177 PMCID:PMC9883169

[101] Sun Y,Hao X.Phase I dose-escalation study of chiauranib, a novel angiogenic, mitotic, and chronic inflammation inhibitor, in patients with advanced solid tumors.J Hematol Oncol2019;12:9

[102] Deng M,Chen K.CS2164 exerts an antitumor effect against human non-Hodgkin’s lymphomas in vitro and in vivo.Exp Cell Res2018;369:356-62

[103] Yuan D,Yu L.CS2164 and venetoclax show synergistic antitumoral activities in high grade B-cell lymphomas with MYC and BCL2 rearrangements.Front Oncol2021;11:618908 PMCID:PMC7988232

[104] Thompson PA,Young NP.Targeting oncogene mRNA translation in B-cell malignancies with eFT226, a potent and selective inhibitor of eIF4A.Mol Cancer Ther2021;20:26-36

[105] Moreau P,Cavo M.Proteasome inhibitors in multiple myeloma: 10 years later.Blood2012;120:947-59 PMCID:PMC4123429

[106] Ravi D,Abermil N.Proteasomal inhibition by ixazomib induces CHK1 and MYC-dependent cell death in T-cell and hodgkin lymphoma.Cancer Res2016;76:3319-31

[107] Graf SA,Gooley TA.Ixazomib-rituximab in untreated indolent B-NHL: an effective, very low toxicity regimen.Blood2020;136:4

[108] Galvez C,Hamadani M.A phase I-II trial of DA-EPOCH-R plus ixazomib as frontline therapy for patients with MYC-Aberrant lymphoid malignancies: the daciphor regimen.Blood2020;136:44-5

[109] Davies AJ,Caddy J.Five-year survival results from the remodl-B trial (ISRCTN 51837425) show improved outcomes in diffuse large B-cell lymphoma molecular subgroups from the addition of bortezomib to R-CHOP chemoimmunotherapy.Blood2022;140(Supplement 1):1770-2

[110] Davies A,Barrans S.Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial.Lancet Oncol2019;20:649-62

[111] Strati P,Davis RE.A phase 1 trial of alisertib and romidepsin for relapsed/refractory aggressive B-cell and T-cell lymphomas.Haematologica2020;105:e26-e8 PMCID:PMC6939506

[112] Gavory G,d’Alessandro A-C.Abstract 3929: identification of MRT-2359 a potent, selective and orally bioavailable GSPT1-directed molecular glue degrader (MGD) for the treatment of cancers with Myc-induced translational addiction.Cancer Res2022;82(12_Supplement):3929

[113] Sesques P.Approach to the diagnosis and treatment of high-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements.Blood2017;129:280-8

[114] Rosenwald A,Advani R.Prognostic significance of MYC rearrangement and translocation partner in diffuse large B-cell lymphoma: a study by the lunenburg lymphoma biomarker consortium.J Clin Oncol2019;37:3359-68

[115] Ott G,Campo E.Understanding MYC-driven aggressive B-cell lymphomas: pathogenesis and classification.Blood2013;122:3884-91

[116] Petrich AM,Smith SM.MYC-associated and double-hit lymphomas: a review of pathobiology, prognosis, and therapeutic approaches.Cancer2014;120:3884-95